Admedus Charts An Eclectic Path To A Global Future
There are not many companies whose R&D business model combines immunotherapies and a medtech cardio franchise, but for Australia’s Admedus it’s a plan that is working so far. And more original science could be added to the portfolio as the company moves increasingly away from its S&D roots.
You may also be interested in...
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Royal Philips closed out the first year of COVID-19 with 7% revenue growth in the fourth quarter. CEO Frans van Houten says low single digit growth is the target for fiscal 2021.
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.